Chronic obstructive pulmonary disease historical perspective: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{{Chronic obstructive pulmonary disease}} {{CMG}}; Philip Marcus, M.D., M.P.H. [mailto:pmarcus192@aol.com]; {{AOEIC}} {{CZ}} ==Overview== '''Chronic obstructive pulmonary...")
 
m (Bot: Removing from Primary care)
 
(19 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
{{Chronic obstructive pulmonary disease}}
{{Chronic obstructive pulmonary disease}}
{{CMG}}; [[Philip Marcus, M.D., M.P.H.]] [mailto:pmarcus192@aol.com]; {{AOEIC}} {{CZ}}
{{CMG}}; '''Associate Editors-In-Chief:''' {{MJ}}, {{MehdiP}}, {{CZ}}


==Overview==
==Overview==
'''Chronic obstructive pulmonary disease''' ('''COPD'''), also known as '''chronic obstructive airway disease''' ('''COAD'''), is a group of [[disease]]s characterized by the pathological limitation of airflow in the [[airway]] that is not fully reversible <ref name="pmid12198919">{{cite journal |author=Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC |title=Chronic obstructive pulmonary disease surveillance--United States, 1971-2000 |journal=[[MMWR. Surveillance Summaries : Morbidity and Mortality Weekly Report. Surveillance Summaries / CDC]] |volume=51 |issue=6 |pages=1–16 |year=2002 |month=August |pmid=12198919 |doi= |url= |accessdate=2012-03-01}}</ref>. COPD is the umbrella term for chronic [[bronchitis]], [[emphysema]] and a range of other lung disorders. It is most often due to [[tobacco smoking]],<ref name="dev">Devereux G. ''ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors.'' [[British Medical Journal|BMJ]] 2006;332:1142-1144. PMID 16690673</ref> but can be due to other airborne irritants such as coal dust, [[asbestos]] or solvents, [[congenital]] conditions such as [[alpha-1-antitrypsin deficiency]] and as well as preserved meats containing nitrites.
For the first time, in 1679, Bonet described a condition of “voluminous [[Lung|lungs]]”. Matthew Baillie illustrated an emphysematous [[lung]] in 1789 and described the destructive character of the condition. In 1808, bronchitis was first described by Charles Badham in England. The terms chronic bronchitis and emphysema were formally defined at the [[CIBA Vision|CIBA]] guest symposium of physicians in 1959. COPD has probably always existed but has been called by different names in the past. The term COPD was first used by William Briscoe in 1965 and has gradually overtaken other terms to become established today as the preferred name for this [[disease]].


==Historical perspective==
==Historical Perspective==
* In 1679, Bonet for the first time described voluminous [[Lung|lungs]].
* In 1721, Ruysh described enlarged [[lung]] airspaces in emphysema.
* In 1769, Giovanni Morgagni described nineteen cases in which the [[Lung|lungs]] were “turgid” particularly from air.
* In 1789, [[Matthew Baillie]] illustrated an emphysematous [[lung]] and described the destructive character of the condition.
* In 1808, bronchitis was first described by Charles Badham in England. He classified acute bronchitis to three forms by his definition (Br. ''acuta, asthenica'' and ''chronica'')<ref name="pmid19343614">{{cite journal |vauthors=Klippe HJ, Kirsten D |title=[200 years of bronchitis--from 1808 to 2008] |language=German |journal=Pneumologie |volume=63 |issue=4 |pages=228–30 |year=2009 |pmid=19343614 |doi=10.1055/s-0028-1119572 |url=}}</ref>
* In 1837, René Laennec, the physician who invented the [[stethoscope]], used the term "emphysema" in his book ''A Treatise on the Diseases of the Chest and of Mediate Auscultation'' to describe [[Lung|lungs]] that did not collapse when he opened the chest during an [[autopsy]]. He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus.<ref name="pmid18046898">{{cite journal |author=Petty TL |title=The history of COPD |journal=Int J Chron Obstruct Pulmon Dis |volume=1 |issue=1 |pages=3–14 |year=2006 |pmid=18046898 |pmc=2706597}}</ref>
* In 1842, John Hutchinson invented the [[spirometer]], which allowed the measurement of the [[vital capacity]] of the lungs. However, his [[spirometer]] could only measure volume, not airflow.<ref name="pmid15849329">{{cite journal |author=Fishman AP |title=One hundred years of chronic obstructive pulmonary disease |journal=Am. J. Respir. Crit. Care Med. |volume=171 |issue=9 |pages=941–8 |year=2005 |month=May |pmid=15849329 |doi=10.1164/rccm.200412-1685OE}}</ref>
* In 1944, Ronald Christie defined the diagnosis for emphysema based on [[dyspnea]] on exertion, after exclusion of [[bronchospasm]], or left [[Congestive heart failure|ventricular failure]].
* In 1947, Tiffeneau and Pinelli, and in 1950 and 1951, Gaensler described the principles of measuring airflow.
* in 1952, Gough explained the [[pathology]] of emphysema.
* In 1956, Barach and Bickerman described treatment for emphysema in their comprehensive textbook.
* In 1959, the terms chronic bronchitis and emphysema were formally defined at the CIBA guest symposium of physicians.
* In 1962, American Thoracic Society Committee on Diagnostic Standards defined the components of COPD and this definition is the foundation of COPD description today.
* In 1964, Gross produced destruction of [[Pulmonary alveolus|alveoli]] and hyperinflation, by injection of [[Pancreas|pancreatic]] extracts (papain) into the airways of guinea pigs.
* In 1965, the term COPD was first used by William Briscoe and has gradually overtaken other terms to become established today as the preferred name for this disease.
* In 1967, Reid described the [[pathology]] of emphysema and other components of COPD.
* In 1976, Thurlbeck illustrated the various types of emphysema in his book.
* In 2003, Choe used [[methylprednisolone]] to produce emphysema in rats. They conclude that systemic [[methylprednisolone]] increases the activity of matrix [[Metalloproteinase|metalloproteinases]] in the lung and causes emphysema. <ref name="pmid12522028">{{cite journal |vauthors=Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF |title=Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats |journal=Am. J. Respir. Crit. Care Med. |volume=167 |issue=11 |pages=1516–21 |year=2003 |pmid=12522028 |doi=10.1164/rccm.200210-1207OC |url=}}</ref>
* In 2004, GOLD offered a new classification of the severity of COPD. <ref name="urlGlobal Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD">{{cite web |url=http://goldcopd.org/ |title=Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD |format= |work= |accessdate=}}</ref>
* In 2005, Voelkel and Taraseviciene-Stewart offered emphysema as an [[Autoimmunity|autoimmune]] [[vascular]] disease. <ref name="pmid16113465">{{cite journal |vauthors=Voelkel N, Taraseviciene-Stewart L |title=Emphysema: an autoimmune vascular disease? |journal=Proc Am Thorac Soc |volume=2 |issue=1 |pages=23–5 |year=2005 |pmid=16113465 |doi=10.1513/pats.200405-033MS |url=}}</ref>
 
== Landmark Events in the Development of Treatment Strategies ==
* In 1956, Barach and Bickerman described treatment for emphysema in their comprehensive textbook.
* In 1980, for treatment of COPD patients, a clinical trial was performed and the use of nocturnal [[oxygen therapy]] for emphysema proved. <ref name="pmid6776858">{{cite journal |vauthors= |title=Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group |journal=Ann. Intern. Med. |volume=93 |issue=3 |pages=391–8 |year=1980 |pmid=6776858 |doi= |url=}}</ref>
* In 1998, Paggiaro performed a multicentre clinical trial of [[Corticosteroid|corticosteroids]] for emphysema treatment.<ref name="pmid9519948">{{cite journal |vauthors=Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J |title=Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group |journal=Lancet |volume=351 |issue=9105 |pages=773–80 |year=1998 |pmid=9519948 |doi= |url=}}</ref>
Below table is a summery of COPD historical prospective:
{| class="wikitable"
!Year
!Investigator
!Landmark event
|-
|1679
|Bonet
|Voluminous [[Lung|lungs]]
|-
|1721
|Ruysh
|Emphysema is enlarged [[lung]] spaces
|-
|1769
|Giovanni Morgagni
| Nineteen cases of air filled lungs
|-
|1789
|[[Matthew Baillie]]
|Destructive character of emphysema
|-
|1808
|Charles
|Bronchitis was first described
|-
|1837
|René Laennec
|Hyper-resonant [[Lung|lungs]] with his invented [[stethoscope]]
|-
|1842
|John Hutchinson
|[[Spirometry]] invention for measurement of the vital capacity of the lungs
|-
|1944
|Ronald Christie
|Clinical definition of emphysema
|-
|1947
|Tiffeneau and Pinelli
|Measuring the air flow in [[spirometry]]
|-
|1952
|Gough
|Emphysema pathology description
|-
|1956
|Barach and Bickerman
|First description for treatment of emphysema
|-
|1959
|CIBA guest symposium of physicians
|The terms [[chronic bronchitis]] and emphysema were formally defined
|-
|1962
|American Thoracic Society Committee on Diagnostic Standards
|Defined the components of COPD
|-
|1967
|Reid
|Described the pathology of emphysema and other components of COPD
|-
|1976
|Thurlbeck
|Illustrated the various types of emphysema
|-
|1980
|[[Oxygen]] therapy trial
|Use of nocturnal [[oxygen]] therapy for emphysema is beneficial
|-
|1998
|Paggiaro
|[[Corticosteroid|Corticosteroids]] for emphysema treatment
|-
|2004
|GOLD criteria
|New classification of the severity of COPD
|-
|2005
|Voelkel and Taraseviciene-Stewart
|Emphysema as an [[Autoimmune disease|autoimmune]] [[vascular]] disease
|}


==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Disease]]
==References==
{{reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
 
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Mature chapter]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 20:58, 29 July 2020

Chronic obstructive pulmonary disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic obstructive pulmonary disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Chronic obstructive pulmonary disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic obstructive pulmonary disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic obstructive pulmonary disease historical perspective

CDC on Chronic obstructive pulmonary disease historical perspective

Chronic obstructive pulmonary disease historical perspective in the news

Blogs on Chronic obstructive pulmonary disease historical perspective

Directions to Hospitals Treating Chronic obstructive pulmonary disease

Risk calculators and risk factors for Chronic obstructive pulmonary disease historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Mehrian Jafarizade, M.D [2], Seyedmahdi Pahlavani, M.D. [3], Cafer Zorkun, M.D., Ph.D. [4]

Overview

For the first time, in 1679, Bonet described a condition of “voluminous lungs”. Matthew Baillie illustrated an emphysematous lung in 1789 and described the destructive character of the condition. In 1808, bronchitis was first described by Charles Badham in England. The terms chronic bronchitis and emphysema were formally defined at the CIBA guest symposium of physicians in 1959. COPD has probably always existed but has been called by different names in the past. The term COPD was first used by William Briscoe in 1965 and has gradually overtaken other terms to become established today as the preferred name for this disease.

Historical Perspective

  • In 1679, Bonet for the first time described voluminous lungs.
  • In 1721, Ruysh described enlarged lung airspaces in emphysema.
  • In 1769, Giovanni Morgagni described nineteen cases in which the lungs were “turgid” particularly from air.
  • In 1789, Matthew Baillie illustrated an emphysematous lung and described the destructive character of the condition.
  • In 1808, bronchitis was first described by Charles Badham in England. He classified acute bronchitis to three forms by his definition (Br. acuta, asthenica and chronica)[1]
  • In 1837, René Laennec, the physician who invented the stethoscope, used the term "emphysema" in his book A Treatise on the Diseases of the Chest and of Mediate Auscultation to describe lungs that did not collapse when he opened the chest during an autopsy. He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus.[2]
  • In 1842, John Hutchinson invented the spirometer, which allowed the measurement of the vital capacity of the lungs. However, his spirometer could only measure volume, not airflow.[3]
  • In 1944, Ronald Christie defined the diagnosis for emphysema based on dyspnea on exertion, after exclusion of bronchospasm, or left ventricular failure.
  • In 1947, Tiffeneau and Pinelli, and in 1950 and 1951, Gaensler described the principles of measuring airflow.
  • in 1952, Gough explained the pathology of emphysema.
  • In 1956, Barach and Bickerman described treatment for emphysema in their comprehensive textbook.
  • In 1959, the terms chronic bronchitis and emphysema were formally defined at the CIBA guest symposium of physicians.
  • In 1962, American Thoracic Society Committee on Diagnostic Standards defined the components of COPD and this definition is the foundation of COPD description today.
  • In 1964, Gross produced destruction of alveoli and hyperinflation, by injection of pancreatic extracts (papain) into the airways of guinea pigs.
  • In 1965, the term COPD was first used by William Briscoe and has gradually overtaken other terms to become established today as the preferred name for this disease.
  • In 1967, Reid described the pathology of emphysema and other components of COPD.
  • In 1976, Thurlbeck illustrated the various types of emphysema in his book.
  • In 2003, Choe used methylprednisolone to produce emphysema in rats. They conclude that systemic methylprednisolone increases the activity of matrix metalloproteinases in the lung and causes emphysema. [4]
  • In 2004, GOLD offered a new classification of the severity of COPD. [5]
  • In 2005, Voelkel and Taraseviciene-Stewart offered emphysema as an autoimmune vascular disease. [6]

Landmark Events in the Development of Treatment Strategies

  • In 1956, Barach and Bickerman described treatment for emphysema in their comprehensive textbook.
  • In 1980, for treatment of COPD patients, a clinical trial was performed and the use of nocturnal oxygen therapy for emphysema proved. [7]
  • In 1998, Paggiaro performed a multicentre clinical trial of corticosteroids for emphysema treatment.[8]

Below table is a summery of COPD historical prospective:

Year Investigator Landmark event
1679 Bonet Voluminous lungs
1721 Ruysh Emphysema is enlarged lung spaces
1769 Giovanni Morgagni Nineteen cases of air filled lungs
1789 Matthew Baillie Destructive character of emphysema
1808 Charles Bronchitis was first described
1837 René Laennec Hyper-resonant lungs with his invented stethoscope
1842 John Hutchinson Spirometry invention for measurement of the vital capacity of the lungs
1944 Ronald Christie Clinical definition of emphysema
1947 Tiffeneau and Pinelli Measuring the air flow in spirometry
1952 Gough Emphysema pathology description
1956 Barach and Bickerman First description for treatment of emphysema
1959 CIBA guest symposium of physicians The terms chronic bronchitis and emphysema were formally defined
1962 American Thoracic Society Committee on Diagnostic Standards Defined the components of COPD
1967 Reid Described the pathology of emphysema and other components of COPD
1976 Thurlbeck Illustrated the various types of emphysema
1980 Oxygen therapy trial Use of nocturnal oxygen therapy for emphysema is beneficial
1998 Paggiaro Corticosteroids for emphysema treatment
2004 GOLD criteria New classification of the severity of COPD
2005 Voelkel and Taraseviciene-Stewart Emphysema as an autoimmune vascular disease

References

  1. ↑ Klippe HJ, Kirsten D (2009). "[200 years of bronchitis--from 1808 to 2008]". Pneumologie (in German). 63 (4): 228–30. doi:10.1055/s-0028-1119572. PMID 19343614.
  2. ↑ Petty TL (2006). "The history of COPD". Int J Chron Obstruct Pulmon Dis. 1 (1): 3–14. PMC 2706597. PMID 18046898.
  3. ↑ Fishman AP (2005). "One hundred years of chronic obstructive pulmonary disease". Am. J. Respir. Crit. Care Med. 171 (9): 941–8. doi:10.1164/rccm.200412-1685OE. PMID 15849329. Unknown parameter |month= ignored (help)
  4. ↑ Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF (2003). "Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats". Am. J. Respir. Crit. Care Med. 167 (11): 1516–21. doi:10.1164/rccm.200210-1207OC. PMID 12522028.
  5. ↑ "Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD".
  6. ↑ Voelkel N, Taraseviciene-Stewart L (2005). "Emphysema: an autoimmune vascular disease?". Proc Am Thorac Soc. 2 (1): 23–5. doi:10.1513/pats.200405-033MS. PMID 16113465.
  7. ↑ "Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group". Ann. Intern. Med. 93 (3): 391–8. 1980. PMID 6776858.
  8. ↑ Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J (1998). "Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group". Lancet. 351 (9105): 773–80. PMID 9519948.

References

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_obstructive_pulmonary_disease_historical_perspective&oldid=1636130"